Follicular lymphoma treatment patterns between 2000 and 2014: a SEER-Medicare analysis of elderly patients

Future Oncol. 2020 Mar;16(8):353-365. doi: 10.2217/fon-2019-0660. Epub 2020 Feb 11.

Abstract

Aim: Characterize follicular lymphoma (FL) treatment patterns among elderly patients using a dataset with longer follow-up time. Materials & methods: Using the linked Surveillance, Epidemiology and End Results-Medicare data, we identified patients diagnosed with FL between 2000 and 2013 with claims data until 2014. We investigated the treatments received and assigned them to lines of treatment. Results: We identified 10,238 elderly patients. Over a 4.7-year median follow-up, 78% of the patients received at least first-line treatment. Fewer individuals received second-line (47%) and third-line (30%) treatments. RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone), RCVP (rituximab, cyclophosphamide, vincristine and prednisolone) and rituximab monotherapy were the most common treatment regimens. Conclusion: One in five elderly patients did not receive FL-directed therapy. The most common treatment regimens were limited to RCHOP, RCVP and rituximab monotherapy.

Keywords: first-line; follicular lymphoma; non-Hodgkin's lymphoma; second-line; third-line; treatment patterns.

Publication types

  • Historical Article

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Combined Modality Therapy
  • Comorbidity
  • Disease Management
  • Female
  • History, 21st Century
  • Humans
  • Lymphoma, Follicular / diagnosis
  • Lymphoma, Follicular / epidemiology*
  • Lymphoma, Follicular / history
  • Lymphoma, Follicular / therapy
  • Male
  • Medicare
  • SEER Program
  • Treatment Outcome
  • United States / epidemiology